Conversion pseudodementia in an elderly subject

Peritogiannis, Vaios; Pappas, Argiro-Irene; Zafiris, Spyros; Pappas, Dimitrios; Mavreas, Venetsanos

doi:10.1186/1744-859x-5-s1-s285

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the limited effectiveness of these interventions, researchers are now more interested in implementing early diagnosis (Saito et al , 2008), disease‐modifying therapeutics (Peritogiannis et al , 2008; Li et al , 2009), and even prevention of dementia (Takahashi et al , 2009). The concept of mild cognitive impairment (MCI) and subjective cognitive impairment (SCI) have been proposed to stimulate the understanding of the earlier, or prodromal, stage of dementia (Takeda et al , 2008), in which the interaction in the aging brain of genetic factors and lifestyle (environmental factors) is the major issue to be elucidated (Azuma et al , 2009).…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenomics of Alzheimer's disease

Takeda

Martínez

Kudo

et al. 2011

Asia-Pacific Psychiatry

View full text Add to dashboard Cite

Recent advances in genomics and pharmacogenomics pose new challenges for the clinical management of dementia. Alzheimer's disease (AD), as the most frequent form of dementia, is a multifactorial/poligenic complex disorder in which hundreds of different genes are potentially involved, leading to the phenotypic expression of the disease in conjunction with epigenetic and environmental phenomena. Disease‐related genomic profiles and genetic variants in genes involved in drug metabolism are responsible for drug efficacy and safety. The field of pharmacogenomics of AD is rapidly expanding and the clinical data of cytochrome c P450 enzymes (CYPs) have been accumulated for clinical application. Interaction of CYP2D6, CYP3A4/5 and AD‐related genes will be discussed in this review. To achieve a mature discipline of pharmacogenomics of AD, the following three aspects are proposed: (a) education of physicians and the public on the use of genetic/genomic screening in daily clinical practice; (b) standardization of genetic testing for major categories of drugs; and (c) validation of pharmacogenomic procedures according to drug category and pathology.

show abstract